Meditoxin® Treatment in Patients With Post Stroke Upper Limb Spasticity

This study is "A Multicenter, Prospective, Randomized, Evaluator Blinded, Comparing Phase 4 Study to Evaluate the Impact of Injection Techniques on the Effectiveness of Botulinum Toxin for the Treatment of Post Stroke Upper Limb Spasticity".

Inclusion criteria

• Male or female subject aged over 20.
• Subjects who has grade 1 + and more spasticity at least one of upper limb muscles as measured on Modified Ashworth Scale after stroke.
• Subjects who was diagnosed stroke at least 1 month prior to study participation.
• Subjects or legal representatives who voluntarily decided the participation of the study and signed the informed consent.

Exclusion criteria

• Subjects who had spinal injuries to be a factor of spasticity except for stroke prior to study enrollment.
• Subjects with allergy or hypersensitivity to the Botulinum Toxin.
• Subjects who have changed the muscle relaxant taking for treatment within past 4 weeks prior to study participation.
• Subjects who have taken injection treatments using alcohol or phenol in upper limb within past 6 months prior to study participation.
• Subjects with general neuromuscular synaptic disorder(e.g. Myasthenia gravis, Lambert-Eaton syndrome, Amyotrophic lateral sclerosis).
• Subjects who have been injected with botulinum toxin within past 3 months before the injection.
• Subjects who are pregnant or lactating of disagreed to avoid pregnancy during 3 months study period.
• Subjects who are scheduled to take part in other clinical trial during the study period.
• Patients who are not eligible for this study at the medical discretion of the investigator.